<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498652</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-206</org_study_id>
    <nct_id>NCT02498652</nct_id>
  </id_info>
  <brief_title>Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects</brief_title>
  <official_title>A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Allopurinol Compared With Allopurinol Administered Alone in Adult Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic
      (PD) effects of RDEA3170 administered in combination with allopurinol compared with
      allopurinol administered alone in adult subjects with gout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2015</start_date>
  <completion_date type="Actual">June 2, 2016</completion_date>
  <primary_completion_date type="Actual">November 19, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 2 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</measure>
    <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
    <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
    <description>Cmax of Allopurinol alone or in combination with RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
    <description>Tmax of Allopurinol alone or in combination with RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</measure>
    <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
    <description>AUC 0-24 of Allopurinol alone or in combination with RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</measure>
    <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
    <description>AUC last of Allopurinol alone or in combination with RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2)</measure>
    <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
    <description>t1/2 of Allopurinol alone or in combination with RDEA3170</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>RDEA3170 2.5 mg, 7.5 mg and 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA3170 5 mg, 10 mg and 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 2.5 mg</intervention_name>
    <description>Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).
Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets).</description>
    <arm_group_label>RDEA3170 2.5 mg, 7.5 mg and 15 mg</arm_group_label>
    <arm_group_label>RDEA3170 5 mg, 10 mg and 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol 300 mg</intervention_name>
    <description>allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)</description>
    <arm_group_label>RDEA3170 2.5 mg, 7.5 mg and 15 mg</arm_group_label>
    <arm_group_label>RDEA3170 5 mg, 10 mg and 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved and is
             willing to provide written informed consent before the first study-related activity.

          -  Subject meets one or more criteria for the diagnosis of gout as per the American
             Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary
             Gout.

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 45
             kg/m2.

          -  Subject has a Screening serum urate level ≥ 8 mg/dL.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment.

        Exclusion Criteria:

          -  Subject is unable to take colchicine for gout flare prophylaxis.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has any gastrointestinal disorder that affects motility and/or absorption.

          -  Subject had unstable angina, New York Heart Association class III or IV heart failure,
             ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to
             Day 1; or subject is currently receiving anticoagulants.

          -  Subject has Screening laboratory parameters that are outside the normal limits and are
             considered clinically significant by the Investigator.

          -  Subject has an estimated creatinine clearance &lt; 60 mL/min calculated by the
             Cockcroft-Gault formula using ideal body weight during the Screening period.

          -  Subject is taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked
             transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable
             for at least 14 days prior to study medication dosing.

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesse Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>December 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>41 subjects were randomized.</recruitment_details>
      <pre_assignment_details>Forty-one subjects were randomized and received at least 1 dose of randomized study medication; 20 subjects in Cohort 1 and 21 subjects in Cohort 2. Subjects were randomized into 1 of 8 sequences across the 2 cohorts (20 subjects each) in a 1:1 ratio.A total of 40 subjects completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Allopurinol 300 mg once daily (qd), 600 mg qd, RDEA3170 2.5 mg qd, 15 mg qd and 7.5 mg qd</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Allopurinol 300 mg qd, 600 mg (300 mg bid), RDEA3170 5 mg qd, 20 mg qd and 10 mg qd</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20">One subject was withdrawn due to noncompliance/protocol violation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Allopurinol 300 mg once daily (qd), 600 mg qd, RDEA3170 2.5 mg qd, 15 mg qd and 7.5 mg qd</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Allopurinol 300 mg qd, 600 mg (300 mg bid), RDEA3170 5 mg qd, 20 mg qd and 10 mg qd</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12.7"/>
                    <measurement group_id="B2" value="48" spread="10.9"/>
                    <measurement group_id="B3" value="49" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
          <units>Maximum Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.2" spread="3.29"/>
                    <measurement group_id="O2" value="-55.0" spread="4.96"/>
                    <measurement group_id="O3" value="-56.8" spread="4.52"/>
                    <measurement group_id="O4" value="-48.1" spread="2.91"/>
                    <measurement group_id="O5" value="-61.0" spread="2.59"/>
                    <measurement group_id="O6" value="-69.5" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.24"/>
                    <measurement group_id="O2" value="4.8" spread="0.38"/>
                    <measurement group_id="O3" value="4.0" spread="0.39"/>
                    <measurement group_id="O4" value="5.5" spread="0.24"/>
                    <measurement group_id="O5" value="4.6" spread="0.22"/>
                    <measurement group_id="O6" value="3.8" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
          <units>Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1065" spread="138"/>
                    <measurement group_id="O2" value="1827" spread="252"/>
                    <measurement group_id="O3" value="2633" spread="255"/>
                    <measurement group_id="O4" value="899" spread="116"/>
                    <measurement group_id="O5" value="958" spread="128"/>
                    <measurement group_id="O6" value="827" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)</description>
          <units>Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400" spread="74.6"/>
                    <measurement group_id="O2" value="517" spread="106"/>
                    <measurement group_id="O3" value="827" spread="136"/>
                    <measurement group_id="O4" value="310" spread="55.5"/>
                    <measurement group_id="O5" value="311" spread="51.8"/>
                    <measurement group_id="O6" value="305" spread="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
          <units>Maximum Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.3" spread="1.78"/>
                    <measurement group_id="O2" value="-54.4" spread="4.50"/>
                    <measurement group_id="O3" value="-50.3" spread="4.15"/>
                    <measurement group_id="O4" value="-57.8" spread="1.61"/>
                    <measurement group_id="O5" value="-66.0" spread="1.86"/>
                    <measurement group_id="O6" value="-73.2" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax)</title>
        <description>Cmax of Allopurinol alone or in combination with RDEA3170</description>
        <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg (qd) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O5">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O6">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O7">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O8">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O9">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax)</title>
          <description>Cmax of Allopurinol alone or in combination with RDEA3170</description>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.03" upper_limit="1.36"/>
                    <measurement group_id="O2" value="2.43" lower_limit="1.94" upper_limit="3.04"/>
                    <measurement group_id="O3" value="1.19" lower_limit="0.997" upper_limit="1.42"/>
                    <measurement group_id="O4" value="1.16" lower_limit="0.911" upper_limit="1.47"/>
                    <measurement group_id="O5" value="1.16" lower_limit="0.937" upper_limit="1.43"/>
                    <measurement group_id="O6" value="1.14" lower_limit="0.905" upper_limit="1.44"/>
                    <measurement group_id="O7" value="1.11" lower_limit="0.928" upper_limit="1.33"/>
                    <measurement group_id="O8" value="1.12" lower_limit="0.877" upper_limit="1.44"/>
                    <measurement group_id="O9" value="1.26" lower_limit="1.02" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>103</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.7</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>92.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.1</ci_lower_limit>
            <ci_upper_limit>110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>102</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.7</ci_lower_limit>
            <ci_upper_limit>120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>88.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.4</ci_lower_limit>
            <ci_upper_limit>101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.7</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.5</ci_lower_limit>
            <ci_upper_limit>119</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
        <description>Tmax of Allopurinol alone or in combination with RDEA3170</description>
        <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg (qd) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O5">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O6">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O7">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O8">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O9">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
          <description>Tmax of Allopurinol alone or in combination with RDEA3170</description>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.500" upper_limit="6.02"/>
                    <measurement group_id="O2" value="2.98" lower_limit="0.983" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.02" lower_limit="0.500" upper_limit="8.00"/>
                    <measurement group_id="O4" value="2.01" lower_limit="0.967" upper_limit="6.00"/>
                    <measurement group_id="O5" value="2.49" lower_limit="0.500" upper_limit="3.97"/>
                    <measurement group_id="O6" value="1.73" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O7" value="2.98" lower_limit="0.500" upper_limit="6.02"/>
                    <measurement group_id="O8" value="1.73" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O9" value="1.97" lower_limit="0.500" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
        <description>AUC 0-24 of Allopurinol alone or in combination with RDEA3170</description>
        <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg (qd) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O5">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O6">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O7">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O8">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O9">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero up to 24 Hours Postdose (AUC 0-24)</title>
          <description>AUC 0-24 of Allopurinol alone or in combination with RDEA3170</description>
          <units>µg·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" lower_limit="3.52" upper_limit="4.42"/>
                    <measurement group_id="O2" value="11.0" lower_limit="8.87" upper_limit="13.7"/>
                    <measurement group_id="O3" value="8.64" lower_limit="7.13" upper_limit="10.5"/>
                    <measurement group_id="O4" value="4.06" lower_limit="3.24" upper_limit="5.10"/>
                    <measurement group_id="O5" value="4.10" lower_limit="3.53" upper_limit="4.77"/>
                    <measurement group_id="O6" value="3.81" lower_limit="3.13" upper_limit="4.64"/>
                    <measurement group_id="O7" value="3.83" lower_limit="3.15" upper_limit="4.65"/>
                    <measurement group_id="O8" value="3.88" lower_limit="3.15" upper_limit="4.77"/>
                    <measurement group_id="O9" value="3.82" lower_limit="3.27" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
        <description>AUC last of Allopurinol alone or in combination with RDEA3170</description>
        <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg (qd) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O5">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O6">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O7">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O8">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O9">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Sampling Timepoint (AUC Last)</title>
          <description>AUC last of Allopurinol alone or in combination with RDEA3170</description>
          <units>µg·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" lower_limit="3.28" upper_limit="4.18"/>
                    <measurement group_id="O2" value="10.9" lower_limit="8.74" upper_limit="13.5"/>
                    <measurement group_id="O3" value="4.25" lower_limit="3.57" upper_limit="5.07"/>
                    <measurement group_id="O4" value="3.59" lower_limit="2.87" upper_limit="4.49"/>
                    <measurement group_id="O5" value="3.76" lower_limit="3.20" upper_limit="4.41"/>
                    <measurement group_id="O6" value="3.71" lower_limit="3.04" upper_limit="4.54"/>
                    <measurement group_id="O7" value="3.53" lower_limit="2.84" upper_limit="4.39"/>
                    <measurement group_id="O8" value="3.74" lower_limit="3.21" upper_limit="4.34"/>
                    <measurement group_id="O9" value="3.74" lower_limit="3.21" upper_limit="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.3</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>98.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>90.4</ci_lower_limit>
            <ci_upper_limit>106</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.5</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>92.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.7</ci_lower_limit>
            <ci_upper_limit>97.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>98.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.0</ci_lower_limit>
            <ci_upper_limit>107</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Informal BE assessment using the conventional BE limits of 80% to 125%</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>97.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.8</ci_lower_limit>
            <ci_upper_limit>102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2)</title>
        <description>t1/2 of Allopurinol alone or in combination with RDEA3170</description>
        <time_frame>Day 7, 14, 21, 28 and 35 (predose through 24 hours postdose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg (qd) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid) (Cohorts 1 and 2)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R1</title>
            <description>Allopurinol 300 mg qd + RDEA3170 2.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O5">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O6">
            <title>Treatment R3</title>
            <description>Allopurinol 300 mg qd + RDEA3170 7.5 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O7">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd (Cohort 2)</description>
          </group>
          <group group_id="O8">
            <title>Treatment R5</title>
            <description>Allopurinol 300 mg qd + RDEA3170 15 mg qd (Cohort 1)</description>
          </group>
          <group group_id="O9">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd (Cohort 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2)</title>
          <description>t1/2 of Allopurinol alone or in combination with RDEA3170</description>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="20"/>
                <count group_id="O9" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.14" upper_limit="1.27"/>
                    <measurement group_id="O2" value="1.47" lower_limit="1.33" upper_limit="1.62"/>
                    <measurement group_id="O3" value="1.25" lower_limit="1.13" upper_limit="1.38"/>
                    <measurement group_id="O4" value="1.20" lower_limit="1.10" upper_limit="1.30"/>
                    <measurement group_id="O5" value="1.14" lower_limit="1.03" upper_limit="1.25"/>
                    <measurement group_id="O6" value="1.17" lower_limit="1.10" upper_limit="1.25"/>
                    <measurement group_id="O7" value="1.16" lower_limit="1.08" upper_limit="1.24"/>
                    <measurement group_id="O8" value="1.13" lower_limit="1.04" upper_limit="1.22"/>
                    <measurement group_id="O9" value="1.13" lower_limit="1.03" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <time_frame>11 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>RDEA3170 2.5 mg, 7.5 mg and 15 mg qd in combination with allopurinol 300 mg (qd and bid)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol.</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.22"/>
                    <measurement group_id="O2" value="5.0" spread="0.61"/>
                    <measurement group_id="O3" value="4.6" spread="0.33"/>
                    <measurement group_id="O4" value="4.8" spread="0.22"/>
                    <measurement group_id="O5" value="4.1" spread="0.22"/>
                    <measurement group_id="O6" value="3.5" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
          <units>Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="952" spread="77.2"/>
                    <measurement group_id="O2" value="2027" spread="203"/>
                    <measurement group_id="O3" value="2138" spread="164"/>
                    <measurement group_id="O4" value="812" spread="76.3"/>
                    <measurement group_id="O5" value="797" spread="65.7"/>
                    <measurement group_id="O6" value="816" spread="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 2 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</title>
        <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
        <time_frame>Screening, Days -1 , 1, 7, 14, 21, 28, and 35 (Pre-dose and Post-dose)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A1</title>
            <description>Allopurinol 300 mg qd</description>
          </group>
          <group group_id="O2">
            <title>Treatment A2q</title>
            <description>Allopurinol 600 mg qd</description>
          </group>
          <group group_id="O3">
            <title>Treatment A2b</title>
            <description>Allopurinol 600 mg (300 mg bid)</description>
          </group>
          <group group_id="O4">
            <title>Treatment R2</title>
            <description>Allopurinol 300 mg qd + RDEA3170 5 mg qd</description>
          </group>
          <group group_id="O5">
            <title>Treatment R4</title>
            <description>Allopurinol 300 mg qd + RDEA3170 10 mg qd</description>
          </group>
          <group group_id="O6">
            <title>Treatment R6</title>
            <description>Allopurinol 300 mg qd + RDEA3170 20 mg qd</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%))</title>
          <description>Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 2)</description>
          <units>Percentage (%) Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372" spread="33.9"/>
                    <measurement group_id="O2" value="645" spread="76.9"/>
                    <measurement group_id="O3" value="681" spread="63.9"/>
                    <measurement group_id="O4" value="268" spread="24.1"/>
                    <measurement group_id="O5" value="267" spread="23.4"/>
                    <measurement group_id="O6" value="286" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>11 Weeks.</time_frame>
      <desc>Total # Affected by any Other Adverse Event includes subjects who may appear more than once; Other Adverse Events were reported for 6 subjects in Cohort 1 and 6 subjects in Cohort 2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>RDEA3170 2.5 mg, 7.5 mg and 15 mg qd in combination with allopurinol 300 mg (qd and bid)</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Reliable urine uric acid values were not obtained due to sample processing errors, and this has resulted in the inability to assess the PD effects of RDEA3170 and/or allopurinol in urine.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jesse Hall, MD</name_or_title>
      <organization>Study Information Center AstraZeneca</organization>
      <phone>(877) 240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

